Registration successful
Account activated – pending validation.
Your account has been activated successfully, but we still need to validate you as a healthcare professional. We’ll send you an email with the result of the validation process in the next [five] days.
In the meantime, you can enjoy access to all the latest news, events and resources on our website
See Anoro Ellipta’s head-to-head data
Anoro Ellipta is the only LAMA/LABA with head-to-head data vs. a LAMA2-5 and vs. two LAMA/LABAs.6 7
Start strong by choosing Anoro Ellipta
as first-line maintenance bronchodilator therapy for your symptomatic adult COPD patients
This is a fictional patient for illustrative purposes.
Anoro Ellipta is indicated as a once-daily maintenance bronchodilator treatment to relieve symptoms in adult patients with COPD.1
Who might benefit from Anoro Ellipta?
Meet Robert
He is a 62-year-old COPD patient being treated with a short-acting bronchodilator agonist therapy (SABA) as required, but is not yet on a maintenance therapy.
Symptoms:
- Breathlessness
- Reduction of usual daily activities
- No features suggestive of asthma or steroid responsiveness
Robert is starting to struggle with climbing stairs and doing household chores. He now watches television instead of going for long walks outside, or dancing with his wife.
Fictional patient for illustrative purposes
References
- Anoro Ellipta SmPC Available at https://www.medicines.ie/medicines/anoro-ellipta-55-micrograms-22-micrograms-inhalation-powder-pre-dispensed-31288/spc
- Maleki-Yazdi M et al. Adv Ther 2016; 33:2188–2199
- GSK data on file RF/UCV/0112/15
- Maleki-Yazdi MR et al. Respir Med 2014;108:1752–1760
- Decramer M et al. Lancet Respir Med 2014;2:472–486.
- Feldman G.J et al. Adv Ther 2017; 34:2518–2533
- Maltais F et al. Adv Ther 2019; 36(9):2434-2449
- Feldman G et al. Int J Chron Obstruct Pulmon Dis 2016;11:719–730.
- Laine DI. Exp Rev Clin Pharmacol 2010;3:43–53.
- Laine DI. J Med Chem 2009;52:2493–2505.
- Slack RJ et al. J Pharmacol Exp Ther 2013;344:218–230
- Hanania N et al. Chest 2012;142:119–127.
- Kempsford R et al. Pulm Pharmacol Ther 2013;26(2):256–264.
- van der Palen J et al. NPJ Prim Care Respir Med 2016;26:16079.
- Svedsater H et al. BMC Pulm Med 2013;13:72–86.
- Riley JH et al. Int J Chron Obstruct Pulm Dis 2016;11:1873–1880.
- Hillman T, Mortimer F, Hopkinson NS. Inhaled drugs and global warming: time to shift to dry powder inhalers. BMJ. 2013 May 28;346:f3359
Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie . Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.
▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.
Anoro is a registered trademark of the GlaxoSmithKline group of companies.
PM-IE-UCV-WCNT-240002 March 2024
